Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Current and future treatment strategies for CLL

Krish Patel • 3 Jun 2021
EHA 2021
Chronic Lymphocytic Leukemia Leukemia Venetoclax

Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, outlines current and future treatment strategies for chronic lymphocytic leukemia (CLL), commenting on the move away from chemotherapy and towards more targeted agents in the frontline setting. In particular, Dr Patel talks on options for patients who have relapsed on both a BTK inhibitor and a BCL-2 inhibitor. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Krish Patel

1:01
The current landscape of antibody-based therapies in R/R DLBCL
Krish Patel • 11 Dec 2023
1:31
Clinical outcomes are poor for CLL patients treated with venetoclax post-BTKi exposure
Krish Patel • 11 Dec 2023
1:25
Hypertension prevalence in CLL and how it is affected by acalabrutinib treatment
Krish Patel • 11 Dec 2023
1:06
Pirtobrutinib in R/R MZL: insights from the BRUIN trial
Krish Patel • 11 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals